Consultation: Reviewing the safety and regulatory oversight of unapproved medicinal cannabis products

Overview

Reviewing the safety and regulatory oversight of unapproved medicinal cannabis products

The purpose of this consultation paper is to gather information on stakeholders’ experiences, observations and knowledge of the use of unapproved medicinal cannabis products. Information obtained will inform regulatory reform options.

The closing date for this consultation is 23.59 AEST on  07 OCTOBER 2025. All submissions received by the deadline, will be considered by the TGA.

Why your views matter

The Therapeutic Goods Administration (TGA) is conducting this consultation in response to growing safety concerns, which appear to correlate with the rapid growth in the number and type of unapproved medicinal cannabis products being accessed in Australia. Information obtained will inform regulatory reform options to ensure appropriate regulatory oversight and market controls are in place, providing assurance of the product quality and safe use of these products.

Consultation paper

Consultation: Reviewing the safety and regulatory oversight of unapproved medicinal cannabis products